Related Experiment Video

Updated: Apr 7, 2026

An Oncogenic Hepatocyte-Induced Orthotopic Mouse Model of Hepatocellular Cancer Arising in the Setting of Hepatic Inflammation and Fibrosis
06:38

An Oncogenic Hepatocyte-Induced Orthotopic Mouse Model of Hepatocellular Cancer Arising in the Setting of Hepatic Inflammation and Fibrosis

Published on: September 12, 2019

9.7K

Efficacy of Sorafenib for Advanced Hepatocellular Carcinoma and Prognostic Factors

Jinpeng Li, Lijun Wang, Ning Cong

    Hepato-Gastroenterology
    |July 10, 2015
    PubMed
    Abstract

    Insights

    Sorafenib effectively treats advanced hepatocellular carcinoma (HCC) with manageable side effects. Lower tumor burden and absence of extrahepatic spread indicate a better prognosis for patients receiving this treatment.

    Area of Science:

    • Hepatobiliary Oncology
    • Medical Oncology
    • Pharmacology

    Background:

    • Sorafenib is approved for advanced hepatocellular carcinoma (HCC).
    • It inhibits key kinases involved in tumor proliferation and angiogenesis.
    • This study evaluates sorafenib's efficacy and prognostic factors in HCC.

    Purpose of the Study:

    • To assess the effectiveness of sorafenib in treating advanced HCC.
    • To identify prognostic factors influencing sorafenib treatment outcomes.
    • To analyze the safety and tolerability profile of sorafenib in HCC patients.

    Main Methods:

    • A cohort of 60 patients with advanced HCC received sorafenib (400 mg BID).
    • Data collected included baseline clinical parameters, adverse events, and survival outcomes.
    • Follow-up included assessment of overall survival (OS) and time to progression (TTP).

    Main Results:

    • Sorafenib treatment resulted in partial response in 3.3% and stable disease in 50.0% of patients.
    • Median overall survival was 13.6 months, and median time to progression was 4.4 months.
    • Common adverse events included dermal reactions (60.0%) and diarrhea (46.7%), generally mild-to-moderate.

    Conclusions:

    • Sorafenib demonstrates efficacy in unresectable primary HCC with acceptable toxicity.
    • Tumor stage, including tumor burden and extrahepatic spread, is a significant prognostic factor.
    • Sorafenib offers a viable treatment option for advanced HCC, with outcomes influenced by disease stage.

    More Related Videos

    A Three-Dimensional Spheroid Model to Investigate the Tumor-Stromal Interaction in Hepatocellular Carcinoma12:24

    A Three-Dimensional Spheroid Model to Investigate the Tumor-Stromal Interaction in Hepatocellular Carcinoma

    Published on: September 30, 2021

    6.3K
    Author Spotlight: Investigating Immune Cell Dynamics in the Tumor Microenvironment — Challenges and Innovations in Cancer Prognosis07:32

    Author Spotlight: Investigating Immune Cell Dynamics in the Tumor Microenvironment — Challenges and Innovations in Cancer Prognosis

    Published on: April 12, 2024

    2.2K

    Related Concept Videos

    Effect of Hepatic Disease on Pharmacokinetics: Pathophysiologic Assessment and Liver Function Test01:22

    Effect of Hepatic Disease on Pharmacokinetics: Pathophysiologic Assessment and Liver Function Test

    In clinical practice, the direct measurement of hepatic blood flow to evaluate liver function presents significant challenges due to the intricate and specialized nature of the necessary techniques. Consequently, healthcare professionals often rely on empirical estimates derived from thorough patient examinations and liver function tests to gauge liver health. Among the tools at their disposal, the Child–Pugh and MELD scoring systems stand out for their ability to categorize and assess...
    257
    Cancer Survival Analysis01:21

    Cancer Survival Analysis

    Cancer survival analysis focuses on quantifying and interpreting the time from a key starting point, such as diagnosis or the initiation of treatment, to a specific endpoint, such as remission or death. This analysis provides critical insights into treatment effectiveness and factors that influence patient outcomes, helping to shape clinical decisions and guide prognostic evaluations. A cornerstone of oncology research, survival analysis tackles the challenges of skewed, non-normally...
    838
    Effect of Hepatic Disease on Pharmacokinetics: Drug Dosing and Hepatic Blood Flow01:26

    Effect of Hepatic Disease on Pharmacokinetics: Drug Dosing and Hepatic Blood Flow

    Chronic liver disease significantly impacts drug metabolism due to alterations in hepatic blood flow and enzyme accessibility. This disruption affects the body's pharmacokinetics—the movement and processing of drugs within the system. Key enzymes crucial for metabolizing medications become less accessible, changing how drugs are processed and utilized. Furthermore, liver disease influences the synthesis of plasma proteins, such as albumin and globulins, which play critical roles in drug...
    340